hans-reniers-lQGJCMY5qcM-unsplash

UK COVID-19 drug developer welcomes NHS treatment priority

  • ILC Therapeutics has welcomed NHS plans to make COVID-19 treatments available to patients as soon as possible.
  • The CEO of NHS England, Sir Simon Stevens, recently highlighted the importance of therapeutic treatments to help the UK return to a more normal way of life.

 

ILC Therapeutics has welcomed NHS plans to make COVID-19 treatments available to patients as soon as possible.

The CEO of NHS England, Sir Simon Stevens, recently highlighted the importance of therapeutic treatments to help the UK return to a more normal way of life, predicting that many of these treatments will be available to COVID-19 patients in 6 -18 months.

ILC Therapeutics is currently developing a synthetic Interferon which has shown great promise against COVID-19 in laboratory testing and will enter clinical trials later this year. It will be the first synthetic Interferon based on the most prominent activities of the natural Interferons.

The Company believes that its synthetic Interferon, called Alfacyte™, will have the potential to prevent COVID-19 hospitalisation in the vast majority of cases by boosting the immune response and preventing the virus from replicating in the body.

Laboratory testing last year showed that Alfacyte™ is at least 20 times more effective than any other therapeutic Interferon in the market.

Alan Walker, CEO of ILC Therapeutics, welcomed Sir Simon Stevens’ position on treatments, stating: “The vaccine roll-out in the UK has been going extremely well and it will play an important role not only in preventing people getting the virus but also in providing therapeutic options that can treat the viral infection.

“A strong therapeutic, such as the synthetic Interferons we are developing, will have the potential to prevent hospitalisations and severe illness.

“This can change the entire complexion of how we fight this virus and enable us to ease social restrictions which have a high cost on society and the economy.

“Most importantly, like the vaccines, it will potentially save many thousands of lives and will be a vital addition to our healthcare armoury, not just against COVID-19 but any viral disease outbreaks in the future.”

ILC Therapeutics is one of two British companies hoping to bring therapeutic Interferons to patients. Its synthetic Interferon Alfacyte™ will enter clinical trials later this year.

This media release generated the following coverage:

Drug Discovery World

Deadline News

High Growth Scotland 

More To Explore

Vacancy

Vacancy for Quality Assurance Manager

A vacancy has arisen for the position of Quality Assurance Manager with ILC Therapeutics at BioCity. Summary The QA Manager shall be responsible for the implementation of the Quality Management System, working with colleagues to ensure compliance with the QMS and with relevant GxP requirements and standards.The QA Manager will

Read More »
Vacancy

Research Associate position

ILC Therapeutics is looking for a proactive and dedicated research associate or senior research associate (depending on the level of experience) who will be a key member of the scientific team. He or she must have validated laboratory skills in immunology. A core part of their role is to develop

Read More »

Share This Post